ArticleNature2023
The evolution of non-small cell lung cancer metastases in TRACERx.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05236114 (TEMPUS GEMINI NSCLC STUDY), which is not on this map. Cited by 165 papers.
0numbers the graph read from it
0cells of the map it votes in
165citing papers in PubMed
56.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)
Who cites it
165 citing papers in PubMed, 220 citations in OpenAlex.
- Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.JCO precision oncology · 2026Trial
- Trial
- Concordance of tumor-informed and tumor-agnostic ctDNA assays for treatment response monitoring in advanced solid tumors.The journal of liquid biopsy · 2026Article
- Clinical metastatic cancer from initiation to colonization: emerging challenges and breakthroughs.Oncogene · 2026Review
- Dissociated skeletal response to first-line immunotherapy in synchronous bone metastatic non-small cell lung cancer patients: Clinical profiles and survival benefit of denosumab adjunction.Journal of bone oncology · 2026Article
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- Review
- Multifocal ground-glass opacities in lung cancer: a narrative review of genomic evolution, immune ecology, and biology-informed clinical management.Journal of thoracic disease · 2026Review
- Phylogenetic and phylodynamic approaches to understanding the evolution of non-small cell lung cancer using single-cell sequencing.Oncogene · 2026Article
- Review
- A tri-component organoid model reveals field-cancerized fibroblasts as key drivers of LUAD recurrence and drug resistance.Molecular therapy. Oncology · 2026Article
- Article
- [Evolution of metastases in non-small-cell lung cancer: preliminary results from the TRACERx-PEACE study].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).International journal of oncology · 2026Review
- Review
- Deconvolution of evolutionary architecture unmasks a high-risk, subclonal-rich subtype in treatment-naive small cell lung cancer.Journal of thoracic disease · 2026Article
- Molecular Residual Disease in Non-Small Cell Lung Cancer: Technology or Patient Outcomes?Journal of personalized medicine · 2026Review
- Agent-Based Simulations of Lung Tumor Evolution Suggest That Ongoing Cell Competition Drives Realistic Clonal Expansions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Hallmarks of lung cancer driven by inhalable particulate matter: From cell-intrinsic oncogenic traits to microenvironment remodeling.Innovation (Cambridge (Mass.)) · 2026Review
- Spatiotemporal heterogeneity in non-small cell lung cancer: A paradigm shift from characterization to dynamic management (Review).Oncology letters · 2026Review
105 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
66 authors at 20 institutions in 9 countries.
Maise Al Bakir *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-0846-8332
Ariana Huebner *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-8009-4999
Carlos Martínez-Ruiz *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-4817-0565
Kristiana Grigoriadis *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-8435-0176
Thomas B K Watkins *Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Oriol Pich *Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1956-1882
David A MooreCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6296-1312
Selvaraju VeeriahCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Sophia WardCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6777-5279
Joanne LaycockCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-3005-1442
Diana JohnsonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Andrew RowanCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Maryam RazaqCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Mita AktherCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cristina Naceur-LombardelliCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Paulina PrymasCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Antonia TonchevaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Sonya HesseyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-9856-424X
Michelle DietzenCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6853-7563
Emma ColliverCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1497-0740
Alexander M FrankellCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-0341-7878
Abigail BunkumCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-7753-9421
Emilia L LimCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Takahiro KarasakiCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-6863-2360
Christopher AbboshCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-8983-1382
Crispin T HileyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Mark S HillCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-0718-8934
Daniel E CookCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-3347-562X
Gareth A WilsonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Roberto SalgadoDepartment of Pathology, ZAS Hospitals, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-1110-3801
Emma NyeExperimental Histopathology, The Francis Crick Institute, London, UK.
Richard Kevin StoneExperimental Histopathology, The Francis Crick Institute, London, UK.
Dean A FennellUniversity of Leicester, Leicester, UK.
Gillian PriceDepartment of Medical Oncology, Aberdeen Royal Infirmary NHS Grampian, Aberdeen, UK.
Keith M KerrUniversity of Aberdeen, Aberdeen, UK.
Babu NaiduBirmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
Gary MiddletonUniversity Hospital Birmingham NHS Foundation Trust, Birmingham, UK.ORCID http://orcid.org/0000-0001-5695-3474
Yvonne SummersDivision of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.
Colin R LindsayDivision of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.
Fiona H BlackhallDivision of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.
Judith CaveDepartment of Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Kevin G BlythSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.
Arjun NairDepartment of Radiology, University College London Hospitals, London, UK.
Asia AhmedDepartment of Radiology, University College London Hospitals, London, UK.
Magali N TaylorDepartment of Radiology, University College London Hospitals, London, UK.
Alexander James ProcterDepartment of Radiology, University College London Hospitals, London, UK.
Mary FalzonDepartment of Cellular Pathology, University College London Hospitals, London, UK.
David LawrenceDepartment of Thoracic Surgery, University College London Hospital NHS Trust, London, UK.
Neal NavaniLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.ORCID http://orcid.org/0000-0002-6412-7516
Ricky M ThakrarLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.
Sam M JanesLungs for Living Research Centre, UCL Respiratory, University College London, London, UK.ORCID http://orcid.org/0000-0002-6634-5939
Dionysis Papadatos-PastosDepartment of Oncology, University College London Hospitals, London, UK.
Martin D ForsterCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Siow Ming LeeCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Tanya AhmadDepartment of Oncology, University College London Hospitals, London, UK.
Sergio A QuezadaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-9763-1700
Karl S PeggsDepartment of Haematology, University College London Hospitals, London, UK.
Peter Van LooCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-0292-1949
Caroline DiveCancer Research UK Manchester Institute Cancer Biomarker Centre, University of Manchester, Manchester, UK.
Allan HackshawCancer Research UK & UCL Cancer Trials Centre, London, UK.ORCID http://orcid.org/0000-0002-5570-5070
Nicolai J BirkbakCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-1613-9587
Simone ZaccariaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-5265-7392
TRACERx Consortium
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. m.jamal-hanjani@ucl.ac.uk.ORCID http://orcid.org/0000-0003-1212-1259
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.ORCID http://orcid.org/0000-0001-9537-4045
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Charles.Swanton@crick.ac.uk.ORCID http://orcid.org/0000-0002-4299-3018
The Francis Crick Institute · GBCancer Research UK · GBLondon Cancer · GBRoyal London Hospital · GBGuy's and St Thomas' NHS Foundation Trust · GBManchester University NHS Foundation Trust · GBUniversity Hospitals of Leicester NHS Trust · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Leicester · GBUniversity Hospital Southampton NHS Foundation Trust · GBGolden Jubilee National Hospital · GBUniversity College Hospital · GBUniversity College London · GBAberdeen Royal Infirmary · GBInstitute of Cancer Research · GBUniversity of Manchester · GBAarhus University · DKCancer Research UK Manchester CentreThe Christie NHS Foundation Trust · GBNHS Greater Glasgow and Clyde · GB
Funding
Cancer Research UK 17786Cancer Research UK 21999Cancer Research UK 24956Cancer Research UK 25349Cancer Research UK 25354Cancer Research UK 29569Cancer Research UK 30025Cancer Research UK CTRNBC-2022/100001Medical Research Council MR/T02481X/1Medical Research Council MR/V033077/1Medical Research Council MR/W025051/1Wellcome Trust CC2008Wellcome Trust CC2041
Abstract
Metastatic disease is responsible for the majority of cancer-related deaths
Indexed as
Carcinoma, Non-Small-Cell LungClonal EvolutionClone CellsEvolution, MolecularLung NeoplasmsNeoplasm MetastasisCohort StudiesDisease ProgressionHumansNeoplasm Recurrence, Local
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05236114ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.